Lasa Supergenerics Ltd. Share Price

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, Akums Drugs and Pharmaceuticals has informed that certain manufacturing sites at Haridwar have been impacted due to labour unrest at SIDCUL industrial area in Haridwar on 14th May, 2026. The unrest has resulted in temporarily disruption of operations and active measures are being taken to normalize the operations. Further updates and assessment of the impact will be informed in due course. Management and the local authorities are in discussions with the workers to resolve the issue quickly & amicably.

The above information is a part of company’s filings submitted to BSE.

In furtherance to its notice dated April 09, 2026 regarding the Postal Ballot by the Company, seeking approval of shareholders by means of special resolution through remote E-voting, to approve the creation of security by way of charge/ mortgage/hypothecation and/or otherwise pursuant to section 180(1)(a) of the companies act, 2013, Yatharth Hospital & Trauma Care Services has informed that the members of the Company have approved the resolution as stated in the Postal Ballot Notice, with requisite majority. The company has enclosed the declaration of the results of Postal Ballot made by the Company, including the voting results in the prescribed format under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Also, it has enclosed the Scrutinizer’s Report dated May 14, 2026, issued by Saurav Upadhyay, Practicing Company Secretary. This disclosure will also be hosted on Company's website:https://www.yatharthhospitals.com/investors/corporate-announcements.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Shree Ganesh Remedies has informed that the Board of Directors of the Company at its meeting held on today, Thursday, May 14, 2026 have considered and approved following: 1. Audited Financial Results (Standalone and Consolidated) of the company for the quarter and the financial year ended on March 31, 2026, along with the reports of Auditors thereon pursuant to Regulation 33 of SEBI LODR Regulations. Copy of the said Financial Results (Standalone and Consolidated) and Auditors Report is enclosed. Pursuant to Regulation 33 of SEBI LODR Regulations, it has declared that the statutory auditors have issued (Standalone and Consolidated) Audit Reports with unmodified opinion on the financial results of the Company for the year ended March 31, 2026; 2. Re-appointment of S N D K & Associates LLP, Chartered Accountants (Firm Registration No: W100060) as an Internal Auditors of the Company for the FY 2026-27. Details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762 /2026 dated January 30, 2026 are given as Annexure ‘A’. The Board of Directors Meeting commenced at 03:30 pm and concluded at 04:10 pm.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of press release titled, ‘Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend’.

The above information is a part of company’s filings submitted to BSE.